Captopril, the first orally active inhibitor of angiotensin-converting enzyme, is used widely in
the treatment of hypertension and congestive heart failure. The pharmacokinetics of this …

The angiotensin converting enzyme inhibitors are an important therapeutic advance in the
treatment of patients with hypertension and congestive heart failure. In addition, they are …

Nine patients with essential hypertension treated with bendroflumethiazide were given
captopril 25 mg orally on three occasions to study the pharmacokinetics and blood pressure …

The pharmacokinetic properties of captopril were studied in two groups of hypertensive
patients:(1) those who had never taken captopril (acute group), and (2) those who had been …

Captopril, an angiotensin‐converting enzyme inhibitor with antihypertensive properties, was
given by mouth and intravenously in 10‐mg doses to five healthy subjects. After intravenous …

The disposition of Captopril, an angiotensin‐converting enzyme inhibitor with
antihypertensive properties, was studied in 10 normal male subjects after a single 100‐mg …

A sensitive assay is described for quantitating plasma captopril levels. Captopril is an orally
active inhibitor of angiotensin-con-verting enzyme. Blood from patients taking this drug was …

The kinetics of captopril plasma levels and of the drug‐induced plasma converting enzyme
activity (PCEA), plasma renin activity (PRA) and diastolic blood pressure (DBP) …

An enhanced, sensitive GC–MS assay is presented for the highly specific angiotensin-
converting enzyme (ACE) inhibitor, captopril. This method improves previously published …

A rapid, simple and sensitive assay was developed for determination of captopril in human
serum. We employed silica gel cartridge for efficient extraction of captopril adduct from …